Results 211 to 220 of about 143,935 (260)
BloodSome of the next articles are maybe not open access.
Related searches:
Related searches:
AML-388: KDM6A Mutation in AML
Clinical Lymphoma Myeloma and Leukemia, 2020Introduction Loss of KDM6A expression has been reported as a potential drug resistance mechanism in AML. Here, we describe the clinical characteristics and treatment outcomes in our cohort of AML patients with KDM6A mutations. Methods We annotated a cohort of 293 AML patients who were treated at our center between Jan 2016 and Dec 2019.
Vijendra Singh +4 more
openaire +1 more source
2009
The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6].
Gheath, Alatrash, Jeffrey J, Molldrem
openaire +2 more sources
The applications of chemotherapy for the treatment of AML have been unchanged over the past three decades, with only 30% of patients demonstrating disease-free survival (DFS) [118]. Despite achieving CR following induction chemotherapy, the majority of patients relapse and succumb to their disease [6].
Gheath, Alatrash, Jeffrey J, Molldrem
openaire +2 more sources
Best Practice & Research Clinical Haematology, 2010
Epigenetic regulation is known to affect gene expression, and recent research shows that aberrant DNA methylation patterning may play a role in leukemogenesis. All leukemias display aberrant distribution of cytosine methylation, which is most notably distributed in specific and distinct signatures in acute myeloid leukemia (AML).
openaire +2 more sources
Epigenetic regulation is known to affect gene expression, and recent research shows that aberrant DNA methylation patterning may play a role in leukemogenesis. All leukemias display aberrant distribution of cytosine methylation, which is most notably distributed in specific and distinct signatures in acute myeloid leukemia (AML).
openaire +2 more sources
The roles of ubiquitination in AML
Annals of Hematology, 2023Acute myeloid leukemia (AML) is a heterogeneously malignant disorder resulting in poor prognosis. Ubiquitination, a major post-translational modification (PTM), plays an essential role in regulating various cellular processes and determining cell fate. Despite these initial insights, the precise role of ubiquitination in AML pathogenesis and treatment ...
Zhifeng Wei, Long Su, Sujun Gao
openaire +2 more sources
Reasons for treating secondary AML as de novo AML
European Journal of Haematology, 2010AbstractIn a Danish bi‐regional registry‐based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML.
Ostgård, Lene Sofie Granfeldt +8 more
openaire +4 more sources
Azacitidine and Venetoclax in AML
New England Journal of Medicine, 2020Comment on the previously published paper.
Sindhura, Chitikela +2 more
openaire +5 more sources